BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 30306577)

  • 1. Uterine sarcomas.
    Mbatani N; Olawaiye AB; Prat J
    Int J Gynaecol Obstet; 2018 Oct; 143 Suppl 2():51-58. PubMed ID: 30306577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uterine sarcomas: a review.
    D'Angelo E; Prat J
    Gynecol Oncol; 2010 Jan; 116(1):131-9. PubMed ID: 19853898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sarcomas and mixed mesodermal tumors of the uterus].
    Günthert AR
    Ther Umsch; 2011 Oct; 68(10):559-64. PubMed ID: 21968895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mesenchymal and mixed uterine tumors : Current overview and practical aspects].
    Lax SF
    Pathologe; 2019 Feb; 40(1):36-45. PubMed ID: 30694356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staging of uterine sarcomas.
    Tse KY; Crawford R; Ngan HY
    Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):733-49. PubMed ID: 21752716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas.
    Seidman JD; Chauhan S
    Int J Gynecol Pathol; 2003 Jan; 22(1):75-82. PubMed ID: 12496702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in uterine sarcoma.
    Gadducci A
    Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):783-95. PubMed ID: 21764643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages.
    Rovirosa A; Ascaso C; Ordi J; Abellana R; Arenas M; Lejarcegui JA; Pahisa J; Puig-Tintoré LM; Mellado B; Armenteros B; Iglesias X; Biete A
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1320-9. PubMed ID: 11955745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma.
    Arita S; Kikkawa F; Kajiyama H; Shibata K; Kawai M; Mizuno K; Nagasaka T; Ino K; Nomura S
    Int J Gynecol Cancer; 2005; 15(2):329-36. PubMed ID: 15823121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endometrial stromal sarcoma of uterus.
    Xue WC; Cheung AN
    Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):719-32. PubMed ID: 21820965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study.
    Le Page C; Almadani N; Turashvili G; Bataillon G; Portelance L; Provencher D; Mes-Masson AM; Gilks B; Hoang L; Rahimi K
    Int J Gynecol Pathol; 2021 Sep; 40(5):487-494. PubMed ID: 33720083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of MR Imaging as a Tool to Differentiate between the Major Histological Types of Uterine Sarcomas.
    Sumi A; Terasaki H; Sanada S; Uchida M; Tomioka Y; Kamura T; Yano H; Abe T
    Magn Reson Med Sci; 2015; 14(4):295-304. PubMed ID: 26104072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current concepts in the imaging of uterine sarcoma.
    Tirumani SH; Ojili V; Shanbhogue AK; Fasih N; Ryan JG; Reinhold C
    Abdom Imaging; 2013 Apr; 38(2):397-411. PubMed ID: 22699695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system.
    D'Angelo E; Spagnoli LG; Prat J
    Hum Pathol; 2009 Nov; 40(11):1571-85. PubMed ID: 19540555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uterine sarcomas: clinical presentation and MRI features.
    Santos P; Cunha TM
    Diagn Interv Radiol; 2015; 21(1):4-9. PubMed ID: 25347940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.
    Croce S; Devouassoux-Shisheboran M; Pautier P; Ray-Coquard I; Treilleux I; Neuville A; Arnould L; Just PA; Belda MALF; Averous G; Leroux A; Mery E; Loussouarn D; Weinbreck N; Le Guellec S; Mishellany F; Morice P; Guyon F; Genestie C
    Gynecol Oncol; 2022 Nov; 167(2):373-389. PubMed ID: 36114030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype.
    Oliva E; Clement PB; Young RH
    Adv Anat Pathol; 2000 Sep; 7(5):257-81. PubMed ID: 10976906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary: Clinicopathologic Characterization With Emphasis on its Distinction From Carcinosarcoma.
    El Hallani S; Arora R; Lin DI; Måsbäc A; Mateoiu C; McCluggage WG; Nucci MR; Otis CN; Parkash V; Parra-Herran C; Longacre TA
    Am J Surg Pathol; 2021 Mar; 45(3):374-383. PubMed ID: 33565764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uterine sarcomas.
    Punnonen R; Lauslahti K; Pystynen P; Kauppila O
    Ann Chir Gynaecol Suppl; 1985; 197():11-4. PubMed ID: 3863523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus.
    Nola M; Babić D; Ilić J; Marusić M; Uzarević B; Petrovecki M; Sabioncello A; Kovac D; Jukić S
    Cancer; 1996 Dec; 78(12):2543-50. PubMed ID: 8952563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.